US · APLM
Apollomics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Foster City, CA 94404
- Website
- apollomicsinc.com
Price · as of 2024-12-31
$16.22
Market cap 22.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $169.11 | +942.6% |
| Intrinsic Value(DCF) | $241.85 | +1,391.06% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $3,742.20 | +22,971.51% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $1,002.00 | $488.60 | $0.00 | $0.00 | $9,538.09 |
| 2022 | $1,050.00 | $1,629.79 | $0.00 | $0.00 | $0.00 |
| 2023 | $74.50 | $29.80 | $0.01 | $0.00 | $0.00 |
| 2024 | $6.39 | $169.11 | $0.00 | $0.00 | $3,742.20 |
AI valuation
Our deep-learning model estimates Apollomics, Inc.'s (APLM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $169.11
- Current price
- $16.22
- AI upside
- +942.6%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$241.85
+1,391.06% upside
Graham-Dodd
—
— upside
Graham Formula
$3,742.20
+22,971.51% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| APLM | Apollomics, Inc. | $16.22 | 22.3M | +943% | +1,391% | — | +22,972% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| ATHA | Athira Pharma, Inc. | $6.75 | 26.62M | — | — | — | — | -0.14 | 0.29 | — | 0.38 | — | 0.29 | 0.00% | — | — | -110.77% | 967.28% | -88.52% | 0.03 | — | 4.18 | 3.90 | 0.49 | -1845.00% | — | -381.00% | -740.33% | -7.40 | 931.82% | 0.00% | 0.00% | 0.00% | 0.37 | 0.38 | — | -13.92 |
| BLRX | BioLineRx Ltd. | $2.83 | 12.31M | +2,367% | — | — | — | -27.55 | 18.87 | 8.78 | 63.67 | — | 84.33 | 67.99% | -70.52% | -31.86% | -69.11% | 441.68% | -17.93% | 1.12 | -2.23 | 1.76 | 1.52 | 1.18 | -8723.00% | 50292.00% | 9178.00% | -17.29% | -2.85 | 950.70% | 0.00% | 0.00% | 1.08% | -12.22 | -5.68 | 8.62 | -9.02 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| ICU | SeaStar Medical Holding C… | $2.76 | 7.7M | — | — | — | — | -0.27 | -3.10 | 50.20 | -0.23 | — | -3.10 | 100.00% | -13216.30% | -18392.59% | 309.35% | 425.16% | -607.76% | -0.26 | -73.12 | 0.55 | 0.28 | 0.05 | -7809.00% | — | 5563.00% | -236.21% | -2.34 | 381.44% | 0.00% | 0.00% | 149.78% | -0.31 | -0.35 | 40.98 | -54.76 |
| LNAI | Lunai Bioworks Inc. | $0.37 | 6.59M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| LPTX | Leap Therapeutics, Inc. | $0.62 | 25.83M | — | — | — | — | -0.24 | 0.47 | — | 0.46 | — | 0.47 | 0.00% | — | — | -141.94% | 631.86% | -110.79% | 0.01 | — | 3.41 | 3.41 | 0.70 | -5452.00% | — | 3782.00% | -365.79% | -4.28 | 543.85% | 1.42% | -0.30% | 1.42% | 0.44 | 0.51 | — | -16.49 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| THAR | Tharimmune, Inc. | $5.12 | 202.4M | — | — | — | — | -0.16 | 1.51 | — | 0.13 | — | 1.51 | 0.00% | — | — | -233.69% | 613.15% | -166.32% | 0.00 | -908.64 | 1.54 | 1.47 | 0.29 | -9121.00% | — | 4934.00% | -553.30% | -4.52 | 537.61% | 0.00% | 0.00% | 0.00% | 0.13 | 0.15 | — | -24.00 |
About Apollomics, Inc.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
- CEO
- Hung-Wen Chen
- Employees
- 13
- Beta
- 1.78
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($241.85 ÷ $16.22) − 1 = +1,391.06% (DCF, example).